)
Savara (SVRA) investor relations material
Savara Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Disease burden and treatment gap
Autoimmune PAP is driven by GM-CSF autoantibodies that impair alveolar macrophage function and surfactant clearance, reducing oxygen delivery and potentially progressing to respiratory failure.
Symptoms include progressive breathlessness, fatigue, reduced exercise tolerance and cough; serious infections occur in 5–13% of patients and account for 18–20% of deaths.
Whole lung lavage is an invasive, hospital-based procedure that does not correct the underlying disease mechanism and may need repetition; long-term effects of repeated procedures are unknown.
Patients averaged 3.5x the comorbidity burden and 167% more outpatient visits, 505% more inpatient visits and 245% more ER visits than matched controls.
Diagnosis averaged 12 months after symptom onset to first physician visit, then 18 months from first visit to diagnosis; aPAP ClearPath testing aims to reduce testing barriers.
MOLBREEVI and IMPALA-2 results
IMPALA-2's primary endpoint, change from baseline in DLCO at Week 24, favored MOLBREEVI over placebo (LSM difference 6.00; p=0.0007); the Week 48 difference was 6.90 (p=0.0008).
SGRQ Total Score improved versus placebo at Week 24 (LSM difference −6.59; p=0.0072); the Week 48 difference was −4.87 (p=0.1046).
SGRQ Activity Score favored MOLBREEVI at Week 24 (difference −7.81; nominal p=0.0149); exercise capacity favored treatment at Week 48 (difference 0.55 peak METs; nominal p=0.0234).
Ground-glass opacity score improved versus placebo at Week 24 (post-hoc p=0.0004); rescue whole lung lavage was used by 7.4% of MOLBREEVI and 13.3% of placebo patients over 48 weeks.
Treatment discontinuation was 3%; none of the MOLBREEVI discontinuations were attributed to drug-related adverse events, and all double-blind completers entered the open-label period.
Longer-term and real-world evidence
Open-label follow-up showed Week 96 DLCO change of +14.7 in patients on MOLBREEVI throughout and +8.8 after placebo-to-MOLBREEVI crossover; retention was 94%.
In a five-patient access case series, all patients responded; reported outcomes included improved lung function and imaging, reduced symptoms, and no WLL after more than one year on treatment.
IMPALA and IMPALA-2 results were published in the New England Journal of Medicine, online in 2020 and 2025, respectively.
- Regulatory review advances as Q3 losses widen and quarter-end liquidity stands at $129.6M.SVRA
Q3 2026 - IMPALA-2 showed DLCO benefit; the FDA decision date is Nov. 22, 2026.SVRA
Corporate presentation - MOLBREEVI shows strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market.SVRA
Corporate presentation - Q2 2026 net loss rose to $40.2M as regulatory reviews and launch preparations accelerated.SVRA
Q2 2026 - MOLBREEVI showed strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market.SVRA
Corporate presentation - MOLBREEVI advances toward approval with strong data, new diagnostics, and robust launch plans.SVRA
Leerink’s Global Healthcare Conference 2025 - Molbreevi's positive phase 3 data positions it for US approval and broad APAP market impact.SVRA
Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025 - All proposals, including director elections and plan amendments, were approved.SVRA
AGM 2026 - MOLBREEVI targets a 5,500-patient US market with strong launch readiness and high approval confidence.SVRA
Jefferies Global Healthcare Conference 2026
Next Savara earnings date
Next Savara earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)